CollPlant Biotechnologies Ltd is classed by the SEC under Orthopedic, Prosthetic & Surgical Appliances & Supplies (industry code 3842), based in Rehovot, IL. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $2 million and a loss of $11 million (its filed statements).
Product businessOrthopedic, Prosthetic & Surgical Appliances & SuppliesRehovot, ILfilings since 20157 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.1 out of ten, 7 of 9 metrics filed and 2 estimated: past 4.7 out of ten, present 4.4 out of ten, future 6.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 7.8 out of ten. No warning events in its filings since 2017. 78th percentile among 29 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.2 out of ten. -10.1% a year over 8 filed years; profitable in 1 of 8. 22nd percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.2 out of ten. CrossAssetData estimate 5.2/10, confidence 35 of 100 (one part). 52nd percentile among 26 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 3.7 out of ten. ROE -189%: lost 189¢ per shareholder dollar. Leverage 44%: owes 44¢ per asset dollar. 37th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.7 out of ten. bottom 47% of 26 in its family; net margin -484.6%. 47th percentile among 26 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.5 out of ten. CrossAssetData estimate 5.5/10, confidence 20 of 100 (family median). 50th percentile among 19 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 6.1 out of ten. top 39% of 25 in its family for room to expand. 61st percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.3 out of ten. top 47% of 25 in its family for growth drivers. 53rd percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 8.5 out of ten. top 15% of 23 in its family for expectations against reality. 85th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-03-26 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-10-09. Filings on record since 2015. Read from EDGAR 2026-10-12.
Where the revenue comes from
By geography: United States 92%, Europe and Other 4%, Canada 4%, Israel under 1%. As tagged in its annual report (Form 20-F, filed 2026-03-26).
Who runs it
Rotem, Eran (Deputy CEO and CFO); Tal, Yehiel (Chief Executive Officer); Abelis, Bar Berta (VP Legal); Bagley, Bowman (VP Commercial North America); Bensimon, Philippe (VP Regulations and QA); Fahimipoor, Oren (VP Operations); Seror, Jasmine (VP Product Development); Evans, Hugh M (director); Havron, Avraham (director); Lask, Alisa (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.